OncoMatch/Clinical Trials/NCT06785636
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Is NCT06785636 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Pocenbrodib and Pocenbrodib and Darolutamide for mcrpc (metastatic castration-resistant prostate cancer).
Treatment: Pocenbrodib · Pocenbrodib and Darolutamide — This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: radio-ligand therapy (PLUVICTO)
Must have received at least 2 cycles of PLUVICTO®
Must have received: androgen receptor pathway inhibitor
1 line of prior any ARPI therapy
Cannot have received: chemotherapy for mCRPC
No prior chemotherapy for mCRPC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MemorialCare Orange Coast Medical Center · Fountain Valley, California
- Cancer and Blood Research Center · Los Alamitos, California
- University of Colorado Health · Aurora, Colorado
- Mount Sinai Medical Center · Miami, Florida
- Emory University Hospital · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06785636 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy for mCRPC disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages